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The tumour vasculature and microenvironment is complex
and heterogeneous, contributing to reduced delivery of cancer
drugs to the tumour. We have developed an in silico model
of drug transport in a tumour cord to explore the effect of
different drug regimes over a 72 h period and how changes
in pharmacokinetic parameters affect tumour exposure to the
cytotoxic drug doxorubicin. We used the model to describe
the radial and axial distribution of drug in the tumour cord
as a function of changes in the transport rate across the cell
membrane, blood vessel and intercellular permeability, flow
rate, and the binding and unbinding ratio of drug within the
cancer cells. We explored how changes in these parameters may
affect cellular exposure to drug. The model demonstrates the
extent to which distance from the supplying vessel influences
drug levels and the effect of dosing schedule in relation to
saturation of drug-binding sites. It also shows the likely impact
on drug distribution of the aberrant vasculature seen within
tumours. The model can be adapted for other drugs and
extended to include other parameters. The analysis confirms
that computational models can play a role in understanding
novel cancer therapies to optimize drug administration and
delivery.
1. Introduction
Resistance to systemic cancer drug treatment is recognized as
a major limitation, not only of cytotoxic chemotherapy but
also of targeted therapies, including tyrosine kinase inhibitors
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and monoclonal antibodies. The resistance of cells to particular drugs can be the result of intrinsic cell
properties (primary resistance) or an adaptive response of the cells to exposure to the drug (secondary
resistance). Different molecular mechanisms are involved in primary and secondary resistance, but a
third class of resistance, pharmacokinetic (PK) resistance, has also been recognized and is relevant to
both cytotoxic and targeted therapies [1,2]. This can be thought of as failure to deliver sufficient drug for
long enough to induce a therapeutic response.
Pharmacokinetic drug resistance can be caused by the failure of a drug to penetrate throughout
the tumour owing to physiological barriers imposed by the biology of the tumour [1]. The tumour
vasculature and microenvironment is complex and heterogeneous, and contributes significantly to the
PK resistance of the cancer cell [3]. Drug delivery is impaired principally because tumour vessels
are distinct from normal tissue capillary networks in that they are poorly organized, inefficient and
structurally different. These combine to generate regions of tumours that are poorly perfused with blood,
leading to the generation of a hypoxic microenvironment and impaired drug delivery [1]. Furthermore,
the presence of ‘leaky’ vessels, in conjunction with a more rigid extracellular matrix and dysfunctional
fibroblasts, leads to elevated interstitial fluid pressure, impaired convective fluid flow and reduced drug
penetration into the tumour [4]. Finally, it has also been argued that PK resistance can exercise a selection
pressure on the tumour, accelerating the emergence of cellular clones resistant to the chemotherapeutic
agent [5].
It is not only the characteristics of the tumour that limit drug penetration and distribution. The
physicochemical characteristics of a drug and its circulating concentration, the plasma PKs, also play
a key role in determining whether the drug reaches therapeutic concentrations throughout the cancer.
Drug absorption (if given orally) and distribution within the patient depend on the drug’s chemical
characteristics. Drug transport through membranes is affected by molecular size, polarity, pH, protein
binding and the potential saturation of specific transporters. Patient characteristics, such as hepatic
and renal function, will also influence drug metabolism and excretion. Drug dose, formulation, route
and schedule of delivery will also impact upon plasma PKs, intra-tumoural drug concentrations and,
ultimately, efficacy and toxicity.
Despite the potential importance of PK drug resistance, this is not a major focus of preclinical
development or clinical trials. Indeed, remarkably little is known about intra-tumoural concentrations or
distribution of most anticancer drugs and their impact, or otherwise, on efficacy and treatment outcome.
There are a number of reasons for this paucity of data, including technical and logistical challenges, and
pressure to reduce animal experimentation in drug development.
Computational models can play a key role in integrating and interpreting experimental and clinical
PK and pharmacodynamic data, including determining the optimal schedule and dose, and response to
therapy [6,7]. These computational models have the potential to reduce development time and cost, and
to accelerate the drug development process. Optimal models need to be clinically relevant, encompass
drug influx and efflux from the cell, include binding to intracellular structures, adapt to the PK profile as
drug is delivered to the tumour and reflect the aberrant tumour vasculature.
We have focused on modelling intra-tumoural drug penetration to develop in silico models based on
existing plasma PK data and experimental in vitro tissue penetration data. For the latter, we employed
a transwell system and developed a model for the cytotoxic drug doxorubicin. We selected doxorubicin
as it remains highly relevant clinically, its PKs have been well characterized and assays are amenable to
this sort of work; there was good agreement between predicted and actual drug concentrations in this
model [8]. Subsequently, we evaluated three computational models of doxorubicin transport through
tumour cord geometry using parameters again based on parameterized in vitro experiments, varying the
PK profile and binding affinity of drug to tumour cells [9]. One genuinely multidimensional model and
two simplified, one-dimensional models, with radial symmetry assumed, gave similar results, and we
were able to demonstrate the impact of altering the PK profile or binding on cell exposure to doxorubicin
at arbitrary distances from a supplying blood vessel.
The aim of this paper is to modify the radially symmetric compartment model to allow for variations
along the vessel supplying the drug (doxorubicin) to the tumour cord, to investigate the effect of altering:
(i) the radius of the vessel, (ii) the permeability of the vessel wall, (iii) the flow velocity of the drug, and
to (iv) explore the balance between drug binding and drug penetration, which is promoted by weaker
drug binding. We explore a number of strategies with the potential to improve drug delivery throughout
the tumour, including one suggested by Hauert et al. [10], in which we model the impact on tumour
exposure to drug of repeat drug administration. The rationale for this approach is that binding sites in
cells close to the vessel delivering drug will become saturated during the initial administration, enabling
more drug to reach the more distant regions of the tumour during subsequent administrations.
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In §2, we first outline the underlying binding model, which is parameterized by experimental data
for doxorubicin, and then describe the full multidimensional tumour cord model and its discretization.
Section 3 contains a summary of the three PK profiles we compare. In §4, a thorough comparison of the
predicted effects owing to each of the PK profiles is presented, and the consequences of varying model
parameters are investigated. These results are then summarized and discussed in §§5 and 6.
2. Models
The work in this paper builds on the one-dimensional, radially symmetric, compartment model we
previously proposed [9]. Three distinct approximations of the radial variation in a longitudinally
uniform tumour cord geometry were compared and we concluded that the quantitative and qualitative
differences between the simulated results were small enough, relative to the uncertainty in the modelling
process and in the experimental data that were used to parameterize the underlying binding processes,
to select the simplest and fastest (referred to in [9] as the radially symmetric compartment model) as the
most appropriate for predictive simulations.
In this paper, we retain the same binding model, which is recapitulated in §2.1 for completeness, and
recall that no explicit elimination or decay of drug is included beyond clearance via the central blood
vessel which supplies the drug initially. This was assumed owing to the lack of functional lymphatics
within tumour tissue, and the lack of data with which we might parameterize any additional generic
clearance within living tissue. Because this omission is likely to render the model invalid for longer time
periods, we limit our simulations to a maximum of 72 h.
In §2.2, we generalize the radially symmetric compartment model of spatial variation of the drug
concentration in a cylindrical tumour cord, centred on a single vessel supplying the drug [9], to allow
for variation along the direction of the supplying vessel. The radial symmetry is retained, but the drug
transport through the tissue is modelled in a two-dimensional plane, in the radial and axial coordinates.
The advective transport of drug within this vessel is also modelled.
2.1. Binding model
The interaction of the chemotherapeutic agent with the microenvironment of cells is restricted to drug
binding only, and described by a three-compartment model, composed of extracellular space (volume V1)
with a concentration C1 of free drug and intracellular space (volume V2) with concentrations C2 and C3
corresponding to free and bound drug (where we understand the term bound to include both DNA-
intercalated drug and drug bound to the cell in other ways). Binding is described by a simple kinetic
model with drug binding reversibly to sites within the cell, which represents the principal form of
binding for doxorubicin in living cells [11].
Applying the principle of mass action leads to three coupled ordinary differential equations which
describe the system [9]:
V1
dC1
dt
= ak1(C2 − C1), (2.1)
V2
dC2
dt
= ak1(C1 − C2) − V2k2C2(C0 − C3) + V2k−2C3 (2.2)
and V2
dC3
dt
=V2k2C2(C0 − C3) − V2k−2C3, (2.3)
in which k1 is the rate constant for the transmembrane transport of drug, a is the area of the interface
between the extracellular and intracellular spaces (the surface area of the cells), k2 and k−2 are the drug
binding and unbinding rates, respectively, and C0 is the concentration of binding sites within the cell.
This model is illustrated by the schematic in figure 1. Values for the kinetic rate constants for the binding
process, given in table 1, have been derived from a bespoke experimental binding assay, outlined in [9].
Remark. The kinetic rate parameters were derived under the assumption that the binding was
reversible. In the limit of irreversible binding, i.e. the limit as β = k−2/k2 → 0 in equations (2.1)–(2.3),
the mass-conserving steady-state solution is given by
Cs1 =Cs2 →
δC1(0) − C0
δ + 1 and C
s
3 →C0 when δC1(0) ≥C0,
and Cs1 =Cs2 → 0 and Cs3 → δC1(0) when δC1(0) <C0.
⎫⎪⎬
⎪⎭ (2.4)
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C1 C2 C3 with C3 £ C0
V1
V2
k1 k2
k
–2
extracellular space
intracellular space
Figure 1. A three-compartmentmodel of drug distribution in tissue. C1 represents extracellular drug concentration, C2 is free intracellular
drug concentration and C3 is bound intracellular drug concentration.
Table 1. Summary of model parameter values for baseline studies. (In the final column, ‘experiment’ refers to the fitting to
experimental data described in [8,9], and ‘histology’ indicates estimation from histological tissue images, such as those illustrated at
www.virtualpathology.leeds.ac.uk. The parameter k0 has been estimated based on the value of r1 (transport rate between cell layers) in
the multilayer model of [8].)
variable value description source of estimate
l 1.6 × 10−5 m vessel radius histology [12]
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Lr 1.96 × 10−4 m cord radius (vessel+ 9 cells) histology [13,14]
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Lz 5.0 × 10−4 m cord length (25 cells) histology [15]
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
r 1.0 × 10−5 m cell radius histology [16]
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
δ 0.0625 extracellular : intracellular volume ratio parameter histology [8,17]
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
α 1.94028 × 105 m−1 membrane surface : tissue volume ratio α = 2/(r√1 + δ)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
k0 2.5 × 10−6 m s−1 permeability between cells experiment [8]
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
k1 1.0 × 10−6 m s−1 permeability across cell membrane experiment [9]
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
k2 0.90 × 10−6 µM−1 s−1 drug binding rate experiment [9]
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
k−2 14.0 × 10−6 s−1 drug unbinding rate experiment [9]
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
β 140/9µM unbinding/binding ratio β = k−2/k2
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
kv 2.8 × 10−6 m s−1 permeability across vessel wall estimate [18]
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
D 5.0 × 10−11 m2 s−1 interstitial diffusion rate D = 2k0r
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
C0 2.6 × 103 µM binding site concentration experiment [9]
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
λ 1.0 × 10−3 m s−1 flow velocity in vessel estimate [19]
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
in which δ =V1/V2 and C1(0) is the initial concentration of extracellular drug. In other words, the drug
continues to bind until either all of the free drug is used up or the binding sites become saturated. These
equations predict a piecewise linear dependence of the steady-state concentrations on C1(0), which is
clearly not mirrored by the experimental data used to fit the model parameters in [9]. Hence, the data
support the assumption that the binding is reversible when using this model to represent the dynamics.
2.2. Spatial model
Previously [9], the binding model was augmented with a spatial component by exploiting the shell-like
nature of tumour cords, the geometric property that cells are broadly arranged in concentric cylindrical
shells around a central blood vessel. In this work, a generalization of that one-dimensional model will be
considered, which retains the cylindrical symmetry but allows variation in the axial direction as well
as the radial direction. This enables the transport of drug along the vessel to be modelled as well as
transport through the tissue.
In our two-dimensional model, we distinguish between the coordinate directions in the definition
of the geometry by using subscripts r and z to represent, respectively, the radial and axial coordinates.
5rsos.royalsocietypublishing.org
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d
r
dz
l
Lr
Lz
Aiz
A
r
i+1/2
Vi
blood flow along central vessel
outer boundary
vessel
simulation domain
(assumes radial symmetry)
cylindrical shell
compartment i, j
in tissue
compartment j
in vessel
Figure 2. Geometry for a two-dimensional cylindrically symmetric compartmentmodel. The rectangle with the thick outline represents
the computational domain.
In tissue, the spatial variation of the discrete drug concentrations are now given by
δ1Vi
dCi,j1
dt
=Ai−1/2r k0(Ci−1,j1 − C
i,j
1 ) + A
i+1/2
r k0(C
i+1,j
1 − C
i,j
1 )
+ Aizk0(Ci,j−11 − C
i,j
1 ) + Aizk0(C
i,j+1
1 − C
i,j
1 ) + aik1(C
i,j
2 − C
i,j
1 ), (2.5)
δ2Vi
dCi,j2
dt
= aik1(Ci,j1 − C
i,j
2 ) − δ2Vik2C
i,j
2 (C0 − C
i,j
3 ) + δ2Vik−2C
i,j
3 (2.6)
and δ2Vi
dCi,j3
dt
= δ2Vik2Ci,j2 (C0 − C
i,j
3 ) − δ2Vik−2C
i,j
3 , (2.7)
for indices i= 1, . . . ,n and j= 1, . . . ,m, where n is the number of shells in the radial direction, m is the
number of discs in the axial direction and ai is the cellular surface area within any compartment in
the ith shell: the volumes of these compartments are independent of the axial index j. The superscripts
correspond, therefore, to the shell and disc indices of the discrete compartments, as illustrated by
compartment i,j in figure 2. In this work, n= 9 and m= 25 are chosen with d= 20µm so that each
shell (and disc) can be approximately identified with a layer of biological cells. The geometry of the
compartments is defined by
Vi = π ((2i − 1)dr + 2l)drdz, Ai+1/2r = 2π (l + idr)dz, Aiz = π ((2i − 1)dr + 2l)dr, (2.8)
in which dr = dz = d gives the dimensions of each compartment. Choosing dr = dz means that the
diffusive transport is isotropic when the permeability k0 is the same in both coordinate directions. Axial
uniformity is assumed in the compartment geometry, so none of the local volumes or areas depends on
the axial index, j. Note that the half-indices represent interfaces between shells.
At the vessel wall boundary the term A1/2r k0(C
0,j
1 − C
1,j
1 ) is replaced by A
1/2
r kv(C
j
v − C1,j1 ), for j=
1, . . . ,m, where Cjv is the concentration of drug in the adjacent part of the supplying vessel. At the
outer boundary in the radial direction, the term An+1/2r k0(C
n+1,j
1 − C
n,j
1 ) is replaced with zero (also for
j= 1, . . . ,m). A no-flux boundary condition is also applied at the boundaries in the axial direction, where
the terms Aizk0(C
i,0
1 − Ci,11 ) and Aizk0(Ci,m+11 − Ci,m1 ) are both replaced with zero along the whole boundary,
i.e. for i= 1, . . . ,n.
The drug concentration in the one-dimensional representation of the vessel, denoted here by Cv , is
modelled using advective transport. This is coupled with the tissue by a term that allows for passage of
drug through the vessel wall into the adjacent layer of cells, and we do not model the plasma binding as
a separate compartment. The variation along the vessel is, therefore, governed by
Vjv
dCjv
dt
= −Ajvλ(Cjv − Cj−1v ) + A1/2r kv(C1,j1 − C
j
v) (2.9)
for j= 1, . . . ,m, where the index j corresponds to the axial index in the adjacent tissue compartment and
C0v =Cv(t) is the predefined PK profile in the blood vessel imposed at inflow, i.e. when j= 1. A blood
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velocity λ drives flow along the vessel and no boundary condition is required at the outflow end of the
vessel segment. The geometry is defined by
Vjv = π l2dz, Ajv = π l2, (2.10)
where dz = d is the width of a disc in the axial direction. The full geometry of the two-dimensional
approximation is illustrated in figure 2, in which the vessel is represented by the central cylinder, and the
values for the geometric and transport parameters are given in table 1.
3. Pharmacokinetic profiles
The clinical PKs of doxorubicin are well characterized in the literature [20]. Doxorubicin concentrations
decay in a tri-exponential manner following intravenous (IV) bolus or infusion and typical parameters
are available in the literature [21], in which doxorubicin is administered as an IV bolus. Clearance of the
drug is modelled via the time dependence of this concentration profile.
The first PK profile considered here, subsequently denoted as PK1, is based on the data [21], in which
Cv(t) is assumed to decay as a tri-exponential (see also [22]) after a short infusion, i.e.:
CPK1v (t) =
⎧⎪⎪⎪⎪⎪⎨
⎪⎪⎪⎪⎪⎩
0 t≤ 0
D0
τ
{
A
A′
(1 − e−A′t) + B
B′
(1 − e−B′t) + C
C′
(1 − e−C′t)
}
0 < t≤ τ
D0
τ
{
A
A′
(eA
′τ − 1)e−A′t + B
B′
(eB
′τ − 1)e−B′t + C
C′
(eC
′τ − 1)e−C′t
}
t> τ ,
(3.1)
where τ is the infusion time, D0 is the dose and parameters A, B, C, A′, B′ and C′ are estimated by taking
averages of the values given in table 2 of [21]. This gives (to three significant figures)
A= 7.46 × 10−2 l−1, A′ = 2.69 × 10−3 s−1,
B= 2.49 × 10−3 l−1, B′ = 2.83 × 10−4 s−1
and C= 5.52 × 10−4 l−1, C′ = 1.18 × 10−5 s−1.
The duration of the perfusion for the total dose injected, τ = 180 s, was also taken from Robert et al. [21]
and the total dose D0 = 1.19827 × 102 µmol was calculated to give an ‘area under curve’ (AUC) of
AUC ≡
∫∞
0
Cv(t) dt= 104 µM s ≈ 2.78µM h, (3.2)
which is typical of what one might find in a patient [23,24]. The AUC is considered to reflect the actual
tumour (i.e. cellular) exposure to drug, and to correlate with toxicity, i.e. to a lesser extent with clinical
efficacy [25].
Two further PK profiles, both constructed to achieve the same AUC, are also considered in this work:
— a profile, denoted by PK2, in which there are three short infusions (to mimic the repeat drug
administration suggested in [10]), each of one-third the dose of CPK1v (t), delivered at 24 h
intervals, i.e.:
CPK2v (t) = 13 (CPK1v (t) + CPK1v (t − 24 × 60 × 60) + CPK1v (t − 48 × 60 × 60)). (3.3)
— a uniform profile, denoted by PK3, representing prolonged exposure at constant concentration
over a period of 3 h, given by
CPK3v (t) =
{
0.926 0 < t≤ 10 800,
0 otherwise.
(3.4)
These three profiles and the accumulation of their AUCs over a period of 72 h are illustrated in the
electronic supplementary material, figures S1 and S2.
4. Results
Numerical experiments were carried out to investigate the effects of changing the PK profile of the
supplied drug (to imitate different modes of delivery) and the model parameters. The computational
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Figure 3. Spatial variation of exposure (
∫ ∗ dt) to extracellular drug, C1 (a,c), and bound drug, C3 (b,d), both at t = 72 h. The black
circles represent ‘exposure’ in the vessel and the surface plots represent exposure in the tissue. Each surface is coloured according to its
height. Parameter values are as in table 1 (standard vasculature) for the top two plots, but modified so that kv → 10 kv , λ → λ/10
and l → l/2 (narrow, leaky vessels) for the bottom two plots. The single short-infusion pharmacokinetic profile, PK1, was used as input.
domain representing the tissue for each simulation consisted of m= 25 compartments in the axial
direction and n= 9 compartments in the radial direction (where each compartment has been chosen
to be approximately the size of a biological cell) and was coupled with a vessel which also consisted of
25 compartments in the axial direction. Equations (2.5)–(2.7) and (2.9) were evolved in time using the
MATLAB function ode15s.
4.1. Varying vessel properties
Figure 3 illustrates the spatial variation of the free extracellular (C1) and bound intracellular (C3)
exposure profiles at 72 h for two sample simulations. The top plots show the results obtained for the
parameters given in table 1; exposure decreases away from the vessel, but changes in the axial direction
are hardly visible over the 500µm length of the simulated domain. The values of the tissue binding and
transport parameters, k0, k1, k2, k−2 and C0, have been estimated for specific cancer cell lines [8,9], but
the vessel-related parameter values, kv , l and λ, are likely to be highly variable in the leaky, chaotic,
vasculature that is characteristic of cancerous tissue. Figure 3c,d illustrates how this might affect the
spatial variation of the exposure by simulating a narrower vessel, with a less obstructive wall and slower
flow; variation in the axial direction is now visible for this particular choice of modified vasculature,
suggesting a higher risk of pharmacokinetic resistance owing to the non-uniformity of the distribution
of drug.
A more thorough examination of the effects of changing parameters is described in the next section.
Each model parameter was varied independently, with all remaining parameters retaining the values
given in table 1. All simulations were run to tmax = 72 h and the output predicted by the model is
illustrated using total exposure to bound drug at specific points in the tissue,
∫tmax
0 C3(x
i,j, t) dt. We treat
this as a determinant of the effect of the drug, in that increasing the exposure to bound drug of a cell
should signify an increased likelihood of efficacy (and/or toxicity).
4.2. Varying model parameters
Figure 4 demonstrates how the exposure to bound drug at two points in the tissue varies as individual
model parameters are changed. In each plot, the exposure is sampled at x1,1, the compartment closest
to the inflow end of the supplying vessel, and xn,m, the compartment furthest from the supply of drug
(which is most likely to exhibit PK resistance). Curves are shown for each of the three PK profiles defined
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Figure 4. (a–f ) Dependence of exposure to bound drug (
∫
C3 dt) at t = 72 h on model parameters, for the two-dimensional,
cylindrically symmetric model: each plot shows the response for all three PK profiles at points ‘near’ to the supply (r = l + 10µm,
z = 10µm) and ‘far’ from the supply (r = l + 170µm, z = 490µm). The vertical dashed lines indicate the standard parameter values
in table 1.
in §3. The model output leads to the following observations which are characteristic of all simulation
results obtained.
— The exposure of tissue to bound drug far from the supply is invariably lower than that close to
the supply.
— The exposure due to a single short infusion (PK1) is lower than that due to a uniform profile
(PK3) with the same AUC, typically by between 5 and 20%. The profile with three short infusions
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(PK2) gives even lower exposures. We emphasize here that the simulations are run to 72 h and
that neither of the short infusion profiles delivers its full AUC within this timescale (as illustrated
in the electronic supplementary material, figure S2).
When the drug concentration throughout the vessel is held at the source concentration, Cv(t),
instead of modelling its escape into the surrounding tissue using equation (2.9), there is no
variation in the axial direction and the concentration in the tissue depends only on the radial
coordinate, indexed by i. This situation is closely approximated when simulations are run with
the parameters given in table 1, as illustrated in figure 3a,b. In this case, as long as the prescribed,
time-dependent profile satisfies Cv(t) → 0 as t→ 0, it can be shown (see appendix A) that∫∞
0
Ci1 dt=
∫∞
0
Ci2 dt=
∫∞
0
Cv(t) dt= AUC ∀i, (4.1)
in which i represents the radial index of the computational shell. In other words, the AUCs for
the free drug compartments are not only independent of the shape of the supplied PK profile but
also equal to the AUC of the supplied profile. For the bound drug
β
∫∞
0
Ci3 dt +
∫∞
0
Ci2C
i
3 dt=C0
∫∞
0
Cv(t) dt ∀i, (4.2)
so its AUC does vary in space and depends on the shape of the supplied profile. However, when
the concentration of bound drug is far from saturating the available binding sites, i.e. when
Ci3 C0 ∀i, it follows that the AUC for the bound drug compartment only depends weakly on
the shape of the supplied PK profile, because
∫∞
0
Ci3 dt≈
C0
β
∫∞
0
Cv(t) dt= C0
β
AUC ∀i. (4.3)
— Close to the vessel, drug exposure increases as β = k−2/k2 decreases, i.e. with stronger binding
and/or weaker unbinding. However, at greater distances from the vessel there is an optimal
value of β, below which the exposure of the tissue to bound drug decreases. This is because,
when binding is relatively strong, the drug is captured by the cells close to the vessel and not
transported to the more distant cells.
The value of β given in table 1 (indicated by the vertical dashed line in the figure) gives a very low
exposure, relative to what might be achieved close to the vessel with stronger binding. However,
it also gives a fairly uniform distribution through the tissue (figure 3b), so all regions of the
tissue receive similar amounts of drug. In fact, the exposure furthest from the supply is close
to the maximum achievable with the other parameters fixed. This is more clearly visible in the
magnified plot shown in figure 5, and in figure 6b, where a ridge indicates the values of the
binding rate k2, and the unbinding rate k−2, for which exposure at a distance from the supply is
maximized.
Figure 6 also shows that (except for very weak unbinding) the exposure depends on the ratio,
β, of binding to unbinding rates and not the separate values of k2 and k−2. This observation
is supported by the mathematical analysis in appendix A, which shows that, in the quasi-one-
dimensional case where there is no variation in the axial direction
C0 − maxt Ci3
β
∫∞
0
Cv(t) dt≤
∫∞
0
Ci3 dt≤
C0
β
∫∞
0
Cv(t) dt ∀i. (4.4)
This does not necessarily hold for small values of β in the fully two-dimensional case because
strong binding causes the free drug concentration in the vessel to vary significantly in the axial
direction.
— Exposure increases with k1, the rate of transport across the cell membrane. However, the value
for k1 given in table 1 (indicated by the vertical dashed line) is in a region of parameter space
where the exposure is insensitive to its value. This confirms the observation made when fitting
the rate parameters to experimental data in [9], in which the value of k1 was chosen to be close
to the minimum that could be taken without significantly changing the fit to the experimental
assay data.
— When the diffusive transport rate in the tissue (represented here by the permeability k0) is varied,
the effect on exposure depends on the distance from the supplying vessel. Close to the vessel the
exposure actually decreases as the diffusion rate increases because, when transport is obstructed,
the drug accumulates close to the vessel. Since it inhibits drug from moving away from the
vessel, a low diffusion rate corresponds to low exposure further from the vessel. When the
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∫
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symmetric model: the plot shows a magnified version of the bottom right corner of figure 4a.
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Figure 6. Dependence of exposure to bound drug (
∫
C3 dt) at t = 72 h on binding rate k2, and unbinding rate k−2, for the two-
dimensional, cylindrically symmetric model with profile PK1: close to the supplying vessel (r = 26µm, z = 10µm, a); far from the
supplying vessel (r = 186µm, z = 490µm, b). Each surface is coloured according to its height. The vertical dashed lines indicate
the standard values of k2 and k−2 in table 1.
diffusion rate is high enough, the drug is uniformly distributed through the modelled region
of tissue, so the exposure is the same throughout.
— Increasing kv , the permeability of the vessel, increases the exposure throughout the tissue. Very
similar behaviour is seen when l, the radius of the supplying vessel, or λ, the velocity of flow in
the vessel, is increased.
4.3. Varying dose
In this paper, we choose predominantly to present the model predictions in terms of exposure to bound
drug, treating it as an indicator of treatment efficacy. Having investigated its dependence on model
parameters, we now analyse the relationship of drug exposure with the dose of drug, D0 in equation (3.1)
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Figure 7. Dependence of exposure to bound drug (
∫
C3 dt) at t = 72 h on dose, D0, for the two-dimensional, cylindrically symmetric
model: close to the supplying vessel (r = 26µm, z = 10µm; a,c); far from the supplying vessel (r = 186µm, z = 490µm; b,d).
In one set of simulations, the binding rate k2, and unbinding rate k−2, are the standard values taken from table 1 (top), in the other, much
stronger binding and weaker unbinding are used (k2 = 2.95 × 10−2 µM−1 s−1 and k−2 = 4.38 × 10−7 s−1, bottom). The vertical
dashed lines indicate the value of D0 in §3.
of §3, for each of the PK profiles presented in that section. Figure 7 shows the dependence of exposure
on dose at positions close to and far from the drug supply.
— For low doses, all three PK profiles give very similar exposures, even though the time variation
of C3 is very different for each profile. The electronic supplementary material, figure S4, provides
an example of how C3 can vary in time at different distances from the supply.
— For high doses, the uniform profile (PK3), representing prolonged subjection to a constant
concentration, gives significantly lower exposure than the other two. The cause is illustrated
in figure 8. For high doses the binding sites rapidly become saturated, i.e. C3 ≈C0: in all cases
the uniform profile (PK3) drops to zero after 3 h, so the drug starts to return to the vessel,
but the two short infusion profiles (PK1 and PK2) continue to supply drug at levels which
maintain saturation for the full 72 h simulation time. It is clear from equation (4.2) that, even
when variation is only allowed in the radial direction, the shape of the supply profile might
have a significant effect on exposure when saturation is approached, though we acknowledge
that profile PK3 has been chosen to represent a specific, exaggerated circumstance which might
be created in vitro but is not physiologically realistic.
— The exposure to bound drug is fairly uniform throughout the computational domain for all doses
when the parameter values from table 1 are used (e.g. figure 3a,b), so very little difference is
seen between the exposures close to and far from the supply in figure 7a,b. However, when
the values of the binding and unbinding rates, k2 and k−2, respectively, are replaced with those
corresponding to the far right corner of the domain in figure 6 (an extreme situation, chosen to
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illustrate the consequences of a microenvironment which supports strong spatial heterogeneity
in drug distribution), significant differences appear between different parts of the tissue, which
are visible in figure 7c,d. The cells furthest from the drug supply now require a dose two orders
of magnitude higher than cells adjacent to the supply if they are to receive the same exposure.
It can also be seen in figure 7 that the exposures of all three PK profiles exhibit similar
dependence on dose when the stronger binding is used. In this case, saturation at high doses is
maintained for longer than with weaker binding when the uniform profile (PK3) is administered,
so the exposures become close to those of both short infusion profiles. For the specific parameter
values chosen here, the exposure due to the profile with three short infusions (PK2) is lowest,
but this does not always hold, e.g. the profiles shown in figure 7a,b indicate that PK2 gives the
greatest exposure of the three for high doses when the original set of parameters (table 1) is used.
Remark. Instead of using exposure to bound drug as an indicator of the response to drug, it could
be assumed that the damage done to a cell by the drug depends monotonically on its exposure to
bound drug; an individual cell might survive if the damage (exposure) is below a particular threshold
value or die if it exceeds that threshold. In models without spatial heterogeneity, the exposure could be
converted into a survival fraction using, for example, a Hill equation [26]; we can imitate this by applying
a threshold to the exposure to bound drug in each computational compartment (the sizes of which have
been chosen to match the size of a biological cell). Applying the same threshold to every compartment is
analogous to using a Heaviside function in place of the Hill equation—it represents the limit as the Hill
exponent tends to infinity (and the higher the Hill exponent, the lower is the phenotypic heterogeneity of
the population). In practice, we do not have the data to allow us to estimate a value for this threshold (and
certainly not its variability between cells), so we provide figure 9 for illustrative purposes only. It shows
the dependence of survival fraction, in the sense defined above, on dose for the two sets of parameters
used to produce figure 7. A low survival threshold was chosen, for which the profile with three short
infusions (PK2) clearly gives lower efficacy, which corresponds to the higher doses required to achieve
this exposure threshold value. However, it can be seen from figure 7 that the order of effectiveness of the
three PK profiles depends on both the threshold value and the choice of model parameters. An extreme
example of this would be applying a threshold of 1.5 × 105 µM h when the parameters from table 1 are
used: in this case three short infusions is the most effective mode of delivery and prolonged exposure at
constant concentration kills no cells at all. Allowing the threshold to vary between cells would tend to
smooth out the transition regions visible in figure 9.
4.4. Varying distance from source
To assess PK resistance for regions where the vasculature is more sparse, we consider a modified
geometry in which an avascular tumour spheroid is surrounded by vascularized tissue in which the
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Figure 10. Dependence of the exposure to bound drug (
∫
C3 dt) at t = 72 h on spheroid radius, for the one-dimensional, spherically
symmetric model: at the edge of the spheroid (a) and in its centre (b). Each plot shows the exposure for all three PK profiles.
drug concentration is that of the specified PK profile. This geometry and the numerical approximation
are described in detail in the electronic supplementary material, S1.3.
Figure 10 shows the dependence of the exposure to bound drug on the radius of the spheroid,
sampling at both the edge and the centre of the spheroid. It can be seen that exposure close to the surface
of the spheroid has very little dependence on the size of the spheroid. However, the exposure to bound
drug of the centre of the spheroid is strongly influenced by its distance from the supply: for the parameter
values given in table 1, the exposure at the centre of a 2 mm radius spheroid has dropped almost to zero.
This region would typically also be nutrient-deficient and possibly necrotic.
5. Discussion
A model of drug transport in a tumour cord has been developed to explore the effect of different drug
delivery schedules and drug-binding parameters on tumour exposure to doxorubicin over a period of
up to 72 h. In particular, we have used the model to assess the benefits of sequential administration
of drug doses and at steady state. In common with all computational approaches, the model makes
a number of simplifications, including neglecting changes in drug clearance beyond that reflected
by the concentration–time curve of drug levels in the central blood vessel. Model parameters have
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been determined a priori from a combination of in vitro experimental findings and the literature.
Importantly, all model parameters (apart from the transport rate across the cell membrane, for which
only a minimum value could be estimated from the experimental assay data) are within or close to the
regions of parameter space in which the exposure is sensitive to their values (indicated by the proximity
of the vertical dashed lines to the regions of the graphs in which exposure is changing rapidly in
figures 4–6). Likewise, small modifications of some of the parameters, representing tumour
vascularization, for example, can potentially have a significant impact on drug delivery and, therefore,
certain drug combinations should be administered carefully. Subject to the caveats above, the model
generates several relevant findings.
Exposure to bound drug is lower further away from the supply, as illustrated in figure 3. This is
intuitively obvious, but mathematical analysis of the model (see appendix A) confirms further that
exposure to bound drug is similar for all three PK profiles, except when saturation of binding sites
is approached; at that point the uniform profile (prolonged subjection to a constant concentration)
gives significantly lower exposures. This is likely to be true not only for tumours but also for healthy
tissues in relation to toxicity. Interestingly, some clinical studies have suggested that continuous infusion
of doxorubicin is associated with less cardiac toxicity than bolus administration [27,28]. This has been
attributed to lower peak drug concentrations, but the model suggests that overall exposure may also be
lower with prolonged infusion of doxorubicin. The effect of drug exposure on distance from the blood
supply, shown in the context of a tumour spheroid in figure 10, demonstrates the challenge of delivering
drug to the avascular, hypoxic core of a tumour. Such regions are recognized as being chemo-resistant
and the model demonstrates the role of PK drug resistance in this context and offers the prospect of
modifying the model parameters to improve delivery to such regions and guide the development of
novel agents with the necessary characteristics [1,29–31].
From a therapeutic perspective, the most effective mode of administration depends on the threshold
of exposure that must be exceeded to kill tumour cells (see figures 7 and 9), as well as the model
parameters (figure 4). As the binding becomes stronger relative to the unbinding, exposure to bound
drug increases close to the supply; further from the supply there is, however, an optimal binding ratio,
above which the exposure to bound drug starts to decrease (shown in figure 4a and in figure 5). While
we have not included an explicit model of cell-kill, this finding implies that drugs which bind avidly
may have reduced clinical effectiveness, as they would fail to reach cells distant from the vessel. An
example may be the monoclonal antibody trastuzumab, which binds to the cell surface HER2 receptor
that is overexpressed in about 15% of breast cancers. Experiments in spheroids suggest that penetration of
trastuzumab deeper into the spheroid may indeed be limited by binding to the superficial cell layers [32].
Exposure to bound drug also increases as: (i) the transport rate across the cell membrane increases;
(ii) the permeability of the wall of the supplying vessel increases; (iii) the radius of the supplying
vessel increases; and (iv) the velocity of the blood flow increases (as illustrated in figure 4). The tumour
vasculature is recognized as being disorganized, with vessels that are more permeable, immature and
tortuous, with inconsistent diameter and impaired blood flow [2]. Our model suggests that these
characteristics of the tumour vasculature may have differing effects on drug exposure. ‘Normalizing’ the
tumour vasculature, as has been shown with the microtubule-targeted cytotoxic eribulin, may enhance
the delivery of anticancer drugs [33]. Likewise, some studies demonstrate that bevacizumab increases the
number of small vessels and tumour perfusion, allowing a better distribution of paclitaxel when given
in combination [34].
When diffusion through the tissue is very rapid, the distribution of drug is uniform (and so is the
exposure to bound drug). When diffusion is slow, exposure to bound drug is high close to the supplying
vessel but rapidly drops away from the vessel (figure 4c). The clinical significance of this observation
is unclear but it is noteworthy that one of the explanations proffered for the very limited efficacy of
chemotherapy in pancreatic cancer is the presence of extensive fibrosis, common within such cancers,
that is postulated to affect drug delivery [35]. The dependence of uniformity of exposure on transport
rate suggests that the raised interstitial pressure observed within tumours will indeed influence drug
penetration and distribution in tumours [4]. Similarly, uniform exposure throughout the tissue (and
hence good drug penetration) is facilitated by fast transport within the vessel, across the vessel wall
and across the cell membrane (figure 4).
The ultimate aim of predictive modelling of the type presented here is the optimization of drug
delivery, but this requires additional knowledge of the dependence of cell survival on the time course
of drug concentration. To illustrate the behaviour of our model, we have chosen to indicate the local
effectiveness of the treatment by the exposure of the tissue to bound drug. However, the toxicity of
doxorubicin is not solely dependent on AUC, particularly at low concentrations, and there is some
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evidence that peak concentration might be a better indicator of cell-kill ([22,26] and references therein).
It would be straightforward to conduct our study using either AUC or peak values of any of the
concentrations in our model, but a better understanding of these dependencies would be required
before the model could be deemed to be truly predictive, and therefore effective in aiding treatment
optimization. We are also aware that, unlike the peak value, the AUC would continue to increase after
the end of the 72 h time window investigated here. Although we believe that we would need a more
realistic model of drug clearance for our model to be valid for longer times, we note that running our
simulations beyond 72 h did not affect the qualitative behaviour of the results.
The model can be adapted to other cytotoxics or molecularly targeted cancer drugs and extended
to include, for example, tumour heterogeneity and different geometries; it can also be applied to other
clinical indications. Particularly attractive is the potential to incorporate the model in drug development
to select agents most likely to achieve uniform distribution of drug at a relevant concentration throughout
the target tissue or tumour. Changing the physico-chemical properties of the drug alters the associated
parameters incorporated in the model, such as binding rates, but the values can be identified from
drug-specific data. This may allow the identification, from a range of candidate molecules, of the
one(s) most likely to address the issue of PK resistance. This could have important implications in
terms of the time and expense of preclinical evaluation, as well as addressing the principles of the 3Rs
(replacement, reduction and refinement) that have been developed as a framework for humane animal
research and subsequently become embedded in guidelines and legislation regulating the use of animals
in scientific procedures.
6. Conclusion
Our model of drug transport in a tumour cord explores the effect of different drug delivery schedules
and tumour-binding parameters on tumour exposure to doxorubicin, using parameters determined
from experimental data. While acknowledging that the model remains a simplification of a complex
system, we believe that such computational models can play an important role in understanding existing
and novel cancer therapeutics by generating quantitative and testable insights that inform further
experiments in the clinically important area of optimizing drug delivery.
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Appendix A. Dependence of exposures on area under curve
We restrict ourselves here to the one-dimensional, cylindrically symmetric case (or, equivalently, the
multidimensional model described in §2.2 with Cjv =Cv(t) imposed in the vessel in place of using
equation (2.9)). We, therefore, consider a model from which axial variation has been removed:
δ1Vi
dCi1
dt
=Ai−1/2k0(Ci−11 − Ci1) + Ai+1/2k0(Ci+11 − Ci1) + aik1(Ci2 − Ci1), (A 1)
δ2Vi
dCi2
dt
= aik1(Ci1 − Ci2) − δ2Vik2Ci2(C0 − Ci3) + δ2Vik−2Ci3 (A 2)
and δ2Vi
dCi3
dt
= δ2Vik2Ci2(C0 − Ci3) − δ2Vik−2Ci3, (A 3)
for i= 1, . . . ,n, where n is the number of shells, and ai is the cellular surface area within the ith shell. The
superscript corresponds to the shell number, and this index increases with distance from the centre of
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the cylindrical coordinates. Half-indices correspond to interfaces between shells. At the inner boundary,
a predefined PK profile, Cv(t), is prescribed, and hence when i= 1, the term A1/2k0(C01 − C11) is replaced
by A1/2kv(Cv(t) − C11) in equation (A 1) (in which k0 has also been replaced by kv , the permeability of the
vessel wall). A no-flux condition is imposed at the outer boundary of the tumour cord by replacing the
term An+1/2k0(Cn+11 − Cn1) with zero when i= n in equation (A 1). The precise values of the geometric
quantities do not matter for the purposes of this proof.
Similar analysis can be applied directly to the spherically symmetric model used in §4.4 and described
fully in the electronic supplementary material, S1.3. However, the following arguments do not hold for
the general two-dimensional model, in which equation (2.9) is used to model flow in the vessel, because
the flux of drug at the outflow end of the central vessel is not known.
First note that each of equations (A 1)–(A 3) can be written in the form
dCik
dt
= fk(Ck) − gk(Ck)Cik, (A 4)
in which i= 1, . . . ,n, is the compartment index, k= 1, 2, 3, is the drug component index, Cl is a vector
containing all the values of Cil except those for which l= k, and fk and gk are linear functions of these
values with non-negative coefficients (as long as Ci3 ≤C0, which is guaranteed in this case by the form of
equation (A 3) and Ci3(0) = 0). As a consequence, since Cik are all initially zero and Cv(t) ≥ 0, the Cik must
remain non-negative for all time.
Now, given any positive integer n, define the local and global masses for each of the drug
compartments
Mik =ViCik, Mk =
n∑
j=1
Mjk, for k= 1, 2, 3, 1 ≤ i≤ n,
so that summing equations (A 1)–(A 3) for all of the compartments and all of the species gives, after
applying the zero-flux boundary conditions,
δ1
dM1
dt
+ δ2 dM2dt + δ2
dM3
dt
=A1/2kv(Cv(t) − C11),
in which we have assumed zero flux through the boundary far from the vessel. Now, since Cv(t) → 0 as
t→ ∞, it must follow that C11 → 0 as t→ ∞, otherwise (since, in this model, Cik ≥ 0, ∀i, k and for all time)
there exist ,T ∈R such that C11 ≥  > 0 for t> T, and the total mass of drug, M= δ1M1 + δ2M2 + δ3M3,
would eventually become negative, which contradicts non-negativity of the concentrations. We can also
define partial masses
Pik =
n∑
j=i
Mjk for k= 1, 2, 3, 1 ≤ i≤ n,
for which it follows, from equations (A 1)–(A 3) and their zero-flux boundary conditions, that
δ1
dPi1
dt
+ δ2
dPi2
dt
+ δ2
dPi3
dt
=Ai−1/2k0(Ci−11 − Ci1) for 2 ≤ i≤ n.
By a similar argument to that above, Ci−11 → 0 as t→ ∞ implies that Ci1 → 0 as t→ ∞ for i= 1, . . . ,n,
since the concentrations and masses must all remain non-negative. This argument can, therefore, be used
repeatedly to show that Ci1 → 0 as t→ ∞ for all i, whatever the value of n. Furthermore, since
δ2
dMi2
dt
+ δ2
dMi3
dt
= aik1(Ci1 − Ci2) for 1 ≤ i≤ n,
it follows that Ci2 → 0 as t→ ∞ for i= 1, . . . ,n. Using this knowledge, and the above argument a
third time
dMi3
dt
=Vik2Ci2(C0 − Ci3) − Vik−2Ci3 for 1 ≤ i≤ n,
implies that Ci3 → 0 as t→ ∞ for i= 1, . . . ,n.
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We now know that all of the compartment concentrations tend to zero as t→ ∞, so we can consider
∫∞
0
δ1
dM1
dt
+ δ2 dM2dt + δ2
dM3
dt
dt=
∫∞
0
A1/2kv(Cv(t) − C11) dt.
The left-hand side of this equation is equal to zero, because the zero concentrations at t= 0, ∞ give
[δ1M1 + δ2M2 + δ2M3]∞0 = 0.
It immediately follows that ∫∞
0
C11 dt=
∫∞
0
Cv(t) dt.
By a similar argument,
0 =
∫∞
0
δ1
dPi1
dt
+ δ2
dPi2
dt
+ δ2
dPi3
dt
dt=
∫∞
0
Ai−1/2k0(Ci−11 − Ci1) dt for 2 ≤ i≤ n,
which implies that ∫∞
0
Ci1 dt=
∫∞
0
Cv(t) dt for 2 ≤ i≤ n.
Finally, for 1 ≤ i≤ n,
0 =
∫∞
0
δ2
dMi2
dt
+ δ2
dMi3
dt
dt=
∫∞
0
aik1(Ci1 − Ci2) dt
⇒
∫∞
0
Ci2 dt=
∫∞
0
Ci1 dt=
∫∞
0
Cv(t) dt
and
0 =
∫∞
0
dMi3
dt
dt=
∫∞
0
Vik2Ci2(C0 − Ci3) − Vik−2Ci3 dt
⇒ k−2
∫∞
0
Ci3 dt + k2
∫∞
0
Ci2C
i
3 dt= k2C0
∫∞
0
Cv(t) dt
⇒ β
∫∞
0
Ci3 dt +
∫∞
0
Ci2C
i
3 dt=C0
∫∞
0
Cv(t) dt.
It follows from this that
C0 − maxt Ci3
β
∫∞
0
Cv(t) dt≤
∫∞
0
Ci3 dt≤
C0
β
∫∞
0
Cv(t) dt. (A 5)
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